Exposure to environmental particulate matter ≤ 10 μm in diameter (PM 10) is associated with an increased risk for giant cell arteritis, particularly in older individuals aged ≥ 70 years and those with ...

Healio spoke with Micaela F. Bayard, MD, a rheumatologist at Mount Sinai and assistant professor of rheumatology at The Icahn School of Medicine, about the treatment landscape in giant cell arteritis.

SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck. Symptoms include, head ...

(RTTNews) - AbbVie (ABBV) Tuesday said the U.S. Food and Drug Administration (FDA) has approved Rinvoq for the treatment of adults with giant cell arteritis (GCA). GCA is an autoimmune disease that ...

Patients with giant cell arteritis started tocilizumab therapy an average of 43 days after diagnosis, partly because of delays in insurance approval. Overall, 82 patients (average age, 73 years; 60% ...

Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Well first off, when you're thinking giant ...

Findings showed 46.4% of patients treated with upadacitinib 15mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has approved ...

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib), 15 mg, once daily, for the treatment ...

(RTTNews) - AbbVie, Inc. (ABBV) announced Friday that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for ...

Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endpoint of sustained remission from week 12 ...

WASHINGTON -- Giant cell arteritis (GCA) can be successfully treated with the oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq), allowing corticosteroids to be withdrawn, results of a phase III ...